ArticlePatient preference and adherence2025
Relative Importance of Disease-Modifying Antirheumatic Drug Attributes for Patients with Rheumatoid Arthritis.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Understanding Patient Preferences for Medication Process Attributes: A Systematic Literature Review.The patient · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Purpose: The significance of fatigue reduction in rheumatoid arthritis (RA) is well recognized. However, prior patient preference studies on disease-modifying antirheumatic drugs (DMARDs) have not adequately explored the relative importance of fatigue reduction compared to other DMARD attributes or accounted for preference heterogeneity. The objective of this study is to determine the relative importance of DMARD attributes, including fatigue reduction, from the patient perspective. Patients and Methods: We conducted a web-based discrete choice experiment (DCE) survey among RA patients in the US. Six DMARD attributes were included: chance of pain reduced by 50% or more, chance of physical function improved by 50% or more, chance of fatigue reduced by 10 points or more, chance of serious side effects, the route and frequency of administration, and out-of-pocket cost per month. Choice sets were constructed using a Bayesian efficient design. Mixed logit (ML) and latent class (LC) models were developed to determine preference weights and to calculate the conditional relative importance of each attribute. Results: Of 228 patients, the ML model showed that the chance of pain reduction had the highest conditional relative importance (2.4), followed by out-of-pocket cost (2.1), the chance of physical function improvement (1.6), the chance of fatigue reduction (1.5), the chance of experiencing serious adverse events (0.6), and the route and frequency of administration (0.09). Preference heterogeneity was observed. The LC model identified two patient classes. The chance of fatigue reduction and the out-of-pocket cost were the most important attributes for class 1 and class 2, respectively. Conclusion: Pain reduction, physical function improvement, fatigue reduction, and out-of-pocket cost were relatively important DMARD attributes for RA patients. However, the presence of preference heterogeneity underscores the need for individualized treatment. Future studies should explore fatigue preferences and generalizability in the broader RA population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.